The transplantation of pancreatic islet cells could restore glycaemic control in patients with type 1 diabetes. Microspheres for islet encapsulation have enabled long-term glycaemic control in rodent models of diabetes; however, humans transplanted with equivalent microsphere formulations have experienced only transient islet graft function owing to a vigorous foreign-body response (FBR), to pericapsular fibrotic overgrowth (PFO) and, in upright bipedal species, to the sedimentation of the microspheres within the peritoneal cavity. Here, we report the results of the testing in non-human primate (NHP) models of seven alginate formulations that were efficacious in rodents, including three that led to transient islet graft function in clinical trials. All formulations elicited significant FBR and PFO 1 month post implantation; however, three chemically modified, immunemodulating alginate formulations elicited a reduced FBR. In conjunction with a minimally invasive transplantation technique into the bursa omentalis of NHPs, the most promising chemically modified alginate derivative (Z1-Y15) protected viable and glucose-responsive allogeneic islets for 4 months without the need for immunosuppression. Chemically modified alginate formulations may enable the long-term transplantation of islets for the correction of insulin deficiency.
C ell encapsulation within semi-permeable hydrogels represents a local immuno-isolation strategy for cell-based therapies without the need for systemic immunosuppression 1, 2 . When applied to the transplantation of islets of Langerhans, this concept represents a functional cure for patients afflicted with insulin-dependent diabetes 2 . The hydrogel sphere facilitates the diffusion of insulin and nutrients necessary for cell function while excluding immune cells that would reject the foreign cells. Alginate spheres are one of the most widely investigated cell encapsulation materials because this anionic polysaccharide forms a hydrogel in the presence of divalent cations under cell friendly conditions. This natural co-polymer can then exhibit differential physical properties depending on the ratio and sequential arrangement of mannuronic and guluronic acid residues, the molecular weight, the concentration and the divalent cations used to form the gels 3 . For instance, alginate with a high guluronic-block content has a higher binding affinity for barium ions and will form a tighter, more stable network compared with the same alginate type crosslinked with calcium 4 . Additionally, electrostatic complexation of a positively charged polymer to the negatively charged alginate surface can provide an outer layer to reduce sphere porosity and increase sphere stability 5 . A final outer alginate layer or chemical modification of the polycation used for coating has been investigated to reduce the positive surface charge density of the sphere [5] [6] [7] . Many alginate sphere formulations produced with variations in the alginate concentration, the crosslinking ion or the inclusion or exclusion of a polycation layer Articles NATuRe BIOMedICAl eNgINeeRINg have demonstrated long-term diabetes correction in rodent models [8] [9] [10] [11] . Unfortunately, these results have not translated at a similar potency when these formulations have been applied to patients with diabetes [12] [13] [14] [15] .
Investigators have reported transient glycaemic control and limited therapeutic benefit to the patients [12] [13] [14] [15] . These studies suggest that the encapsulated islet cells are not remaining viable following transplantation into the general intraperitoneal space of humans. Based on the reported clinical observations and experimental animal data, we hypothesized that the major contributing factors to the loss of cell function include pericapsular fibrotic overgrowth (PFO), sphere aggregation and inadequate metabolite supply of the transplantation site [14] [15] [16] [17] [18] [19] [20] . PFO results from a foreign-body response (FBR) to the implantable material, with deposition of an extracellular matrix and cellular network to wall off the foreign entity from the body 21 . This fibrotic network then affects graft viability by restricting oxygen and metabolite diffusion into the spheres 22 . Clumping of the spheres can further diminish nutrition by increasing exchange distances to the cells housed in the centre of the clumps 16, 17 . Clumping of the microspheres occurs more commonly in bipedal animals due to gravity-based sedimentation into the lowest point of the peritoneal cavity, the Douglas space. Moreover, the intraperitoneal transplantation site has been reported to be a hypoxic environment for islets, with low oxygen partial pressure (pO 2 ) levels that may not support healthy endocrine function 18 .
To test our hypothesis, we chose a non-human primate (NHP) animal model that is bipedal, genetically, immunologically and anatomically more similar to humans than rodents, dogs or pigs, and would provide a better surrogate model before testing in humans 23 . Similar to humans, NHP models are exposed to diverse sets of antigens compared to inbred rodents raised in sterile environments 24 , and the longer life-time of exposure to somatic mutations may allow the immune system of NHPs to better identify and combat distinctive foreign entities within the body 25 .
First, we sought to investigate whether the NHP model could recapitulate the outcomes of humans transplanted with the same alginate sphere formulations [12] [13] [14] [15] . Three alginate formulations, previously tested in humans with transient encapsulated islet graft function, were formulated without islets and implanted into the general intraperitoneal space (greater sac) of NHPs. Each of the clinical alginate formulations elicited a significant FBR and PFO in the NHPs. PFO was described as a major contributor to loss of cell viability in patients and our results illustrate that the NHP model can recapitulate findings from patients transplanted with the same material formulations. In contrast, three immune-modulating alginate formulations (Z1-Y19, Z2-Y12 and Z1-Y15) 26, 27 were found to mitigate the FBR and PFO in NHPs, with two chemically modified formulations (Z2-Y12 and Z1-Y15) being the most effective in preventing PFO. An alternative transplantation technique into the bursa omentalis (lesser sac of the peritoneal cavity) was then developed to impede sphere clumping, and the most promising chemically modified alginate derivative (Z1-Y15) was further evaluated for potential allogeneic islet transplantation in NHPs. When retrieved after 1 month and 4 months post transplantation, the Z1-Y15 encapsulated islets were free of PFO in 6 out of 7 NHPs, with a median islet cell viability of 93.5% after 1 month and 90.0% after 4 months. In vitro assessments performed on the retrieved Z1-Y15 encapsulated islets indicated functional engrafted endocrine tissue, which further suggests that the bursa omentalis transplantation site (pO 2 levels of 35.0 ± 3.2 mmHg) can support encapsulated islets if devoid of fibrotic overgrowth to ensure free nutritional exchange. Combining these design principles promoted islet viability for the duration of the study (4 months post transplantation) in NHPs without the use of any immunosuppression. This work provides the foundation for proof-of-concept clinical trials with encapsulated isolated pancreatic islets from deceased organ donors.
Clinical trial alginate formulations elicit FBRs in NHPs
Each of the sphere formulations used in both the human clinical trials and NHP studies presented here were produced according to the design criteria presented in Table 1 . In addition, to ensure that the microspheres were as close as possible to the ones used in the clinical trials, they were produced by the original inventors after technology transfer to the University of Illinois at Chicago (UIC) (A-PLO-A and UPMVG-Ca 2+ /Ba 2+ ) or shipped from the original laboratory conducting the clinical trials (UPMVG-Ba 2+ ). The alginate-(poly-L-ornithine)-alginate (A-PLO-A) spheres were produced with a 1.7% wt/vol. custom-made highly purified alginate, crosslinked with 109 mM calcium, and an additional polycation layer (PLO) was added to restrict sphere permeability 12, 13 . An outer alginate layer was added to reduce the surface positive charge 5 . The UPMVG-Ba 2+ spheres were produced with a 2.2% wt/vol. "ultrapure medium viscosity high guluronic acid content" alginate composition and crosslinked with 20 mM barium 14 . In comparison to calcium crosslinked alginate spheres, barium spheres have a higher modulus of elasticity, reduced permeability with respect to IgG penetration, and are less susceptible to swelling under osmotic pressure changes 9, 28 . The UPMVG-Ca 2+ /Ba 2+ spheres were produced with a 1.8% wt/vol. "ultra-pure medium viscosity high guluronic acid content" alginate composition and crosslinked with 50 mM calcium and a low concentration of 1 mM barium 15, 29 . This divalent cation combination was found to reduce the swelling of calcium alginate spheres under osmotic pressure changes while reducing the barium content, as free barium can be toxic at high levels 30 . Ca 2+ /Ba 2+ spheres are reported to have an intermediate modulus of elasticity with respect to calcium and barium crosslinked spheres, but an IgG permeability equivalent to calcium crosslinked spheres 29 . While each of the sphere formulations evaluated in the clinical trials were produced with distinct variations in physical properties, such as elastic modulus or permeability, the ideal hydrogel properties that can provide optimal immunoprotection of cells without compromising cell nutrition remain unclear 31 .
To mimic the formulations used in clinical trials [12] [13] [14] [15] , each of the alginate sphere formulations (A-PLO-A, UPMVG-Ba 2+ and UPMVG-Ca 2+ /Ba 2+ ) were produced without islets and were 0.5 mm in size. These were implanted into the general intraperitoneal space of NHPs via minimally invasive laparoscopic surgery 17 . After 1 week, all three of the clinical alginate sphere formulations began to show signs of cellular attachment ( Fig. 1a ). By 1 month, each became enveloped in fibrotic tissue that could not be retrieved by repeated peritoneal lavage procedures or by mechanical agitation (Fig. 1b) . These findings are similar to the reports of the human clinical trials, whereby the spheres were adhered to omental tissue 14, 15 . Haematoxylin and eosin (H&E) and immunohistochemical staining of retrieved samples showed multicellular layers surrounding the spheres (Fig. 1a ) that were composed of foreign body giant cells, CD11b + myeloid cells and smooth muscle actin (SMA)positive myofibroblasts ( Supplementary Fig. 1 ). These results are consistent with cellular populations involved in FBRs to implantable materials 32 . The majority of the responding CD11b + cells to alginate microspheres has recently been identified as CD68 + macrophages 21 . The three empty sphere formulations (A-PLO-A, UPMVG-Ba 2+ and UPMVG-Ca 2+ /Ba 2+ ) elicited similar fibrotic responses post implantation in NHPs compared to humans transplanted with the same alginate sphere formulations containing allogeneic islets ( Fig. 1a,b ).
Chemically modified alginates reduce FBRs in NHPs
In contrast to the above clinically tested spheres, a combinatorial approach was taken to apply unique chemical modifications to an alginate polymer backbone in order to identify sphere formulations with reduced fibrotic potential. Of the 774 alginate derivatives created, three lead chemically modified alginate derivatives were found to exhibit antifibrotic properties after in vivo screening in the Articles NATuRe BIOMedICAl eNgINeeRINg C57BL/6J mouse model 26 . This mouse strain exhibits strong FBRs to implantable materials that are similar to the fibrotic responses observed in humans 33 . The impact of sphere size was similarly investigated in the C57BL/6J mouse model, and, interestingly, 1.5mm diameter plain alginate spheres were shown to illicit less fibrosis following implantation compared to conventional 0.5-mm diameter spheres 27 . The combination of both the antifibrotic alginate and an optimal sphere size was tested with stem cell-derived human beta cells, and these spheres enabled long-term glycaemic control in the immune-competent C57BL/6J mouse model of diabetes 34 .
We sought to determine whether the antifibrotic nature of the chemically modified alginate derivatives and larger sized spheres seen in C57BL/6J mice would translate similarly in NHPs. The chemically modified alginate analogues were synthesized and coformulated with an unmodified high molecular weight SLG100 alginate as previously reported 26 . Three modified alginate derivatives (Z1-Y19-Ba 2+ , Z2-Y12-Ba 2+ and Z1-Y15-Ba 2+ ) and a plain alginate (SLG20-Ba 2+ ) were then formulated as empty spheres at the 1.5-mm size and evaluated in NHPs (Table 1 ). Contrary to the previous clinical alginate sphere formulations, each type of the 1.5-mm spheres was easily flushed from the general intraperitoneal space 1 month post implantation (Fig. 1c ). The amount of PFO coverage of the 1.5-mm spheres was substantially improved compared to previous clinical alginate formulations at the 0.5-mm size, and two chemically modified alginate derivatives (Z2-Y12-Ba 2+ and Z1-Y15-Ba 2+ ) were found to be the most effective at mitigating the FBR in NHPs ( Fig. 1d ; Supplementary Table 1 ).
the bursa omentalis transplantation site
Despite these results, we observed that the modified alginate spheres transplanted near the lobes of the liver within the general intraperitoneal space ( Fig. 2a , top left) tended to descend over time and aggregate in the Douglas space (base of the peritoneal cavity) ( Fig. 2a , bottom left). It has been hypothesized that nonfibrosed spheres undergo gravitational sedimentation within the intraperitoneal space of bipedal animals, which can lead to clumping of encapsulated islets and diminished islet functionality 16, 17 . Clumping of encapsulated islets was further noted as a potential cause for graft failure in the clinical trials 15 . To avoid this, we sought to develop methods to impede settling and clumping of encapsulated cell technologies within the Douglas space.
The peritoneal cavity contains discrete compartments separated by layers of peritoneum ( Fig. 2 ). We hypothesized that spheres could be introduced behind the general intraperitoneal space (greater sac) and into the bursa omentalis compartment (lesser sac). This approach would constrain the spheres within the tissue bilayer formed by the greater omentum. The friction of the bursa omental folds draping the spheres would then limit sphere movement and clumping. To perform the bursa omentalis transplantation technique, a small incision is introduced laparoscopically into an avascular section of the gastrocolic ligament. Alternatively, the bursa omentalis can be approached via the foramen of Winslow. The spheres are then infused into the bursa omentalis ( Fig. 2a , top right; Supplementary Video 1). Over time, we observed that the spheres would distribute uniformly as a monolayer between the two vascularized omental layers ( Fig. 2a (bottom right),b).
pO 2 measurements of alternative transplantation sites
Hypoxia within the intraperitoneal transplantation site is another proposed cause of failure of encapsulated islet grafts. The pO 2 levels within the peritoneal cavity may not support healthy endocrine function. However, oxygen measurements of the intraperitoneal For the clinical trial sphere formulations (A-PLO-A, UPMVG-Ba 2+ and UPMVG-Ca 2+ /Ba 2+ ), very few spheres were retrieved at 4 weeks, so histograms are depicted as mostly fibrosed dark red. SLG20-Ba 2+ , n = 95 spheres assessed from 1 NHP; Z1-Y19-Ba 2+ , n = 143, 76 and 68 spheres assessed from 3 NHPs; Z2-Y12-Ba 2+ , n = 174, 129 and 125 spheres assessed from 3 NHPs; Z1-Y15-Ba 2+ , n = 84, 120 and 64 spheres assessed from 3 NHPs. Note that data presented for empty SLG20-Ba 2+ , Z1-Y19-Ba 2+ , Z2-Y12-Ba 2+ and Z1-Y15-Ba 2+ spheres are from unpublished results within NHP cohorts for datasets collected in previously published reports 26, 27 .
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NATuRe BIOMedICAl eNgINeeRINg site using small animal models have reported large ranges in pO 2 (15-79 mmHg), and in situ pO 2 of islets has been reported at 40 mmHg [35] [36] [37] [38] . Due to these discrepancies, we sought to investigate the pO 2 within the intraperitoneal site and sought alternative transplantation sites for islets using a more clinically relevant NHP model. Alternative transplantation sites, including the peritoneal cavity, omental pouch, intrahepatic, kidney capsule, subcutaneous, intramuscular, intra-epididymis and bone marrow cavity, for microencapsulated islets have previously been investigated in rodents and/or NHPs [39] [40] [41] [42] [43] [44] [45] [46] . The ideal transplantation site should have the following attributes: (1) not produce an acute inflammatory response post transplantation; (2) be a large enough space to accommodate the encapsulated islet graft; (3) provide sufficient oxygenation and exchange of metabolites; (4) be easily accessible for implantation and . Bursa omentalis transplantation: the stomach was lifted using a laparoscopic grasper and a small incision was made into an avascular section of the gastrocolic ligament (top right). The Z1-Y15 spheres were then infused into the bursa omentalis (blue; centre). At 1 month post implantation, the Z1-Y15 spheres remained spatially dispersed within the bilayer of the greater omentum (bottom right). A schematic of the two transplantation methods provides the location of the anatomical sites and a summary of the spatial distributions of the Z1-Y15 spheres during the 1-month retrievals (centre). The general intraperitoneal space transplantation was repeated independently for n = 10 NHPs, and the bursa omentalis transplantation for n = 7 NHPs, and similar spatial distributions were obtained. b, The greater omentum was extracted through the supra umbilical midline incision at 1 month and shows translucent, unattached Z1-Y15 spheres with encapsulated allogeneic islets within the omental tissue bilayer. Sections of the greater omentum were excised to flush out encapsulated allogenic islets free of PFO depicted in Fig. 3 . c, pO 2 values of various transplantation sites that have been previously investigated for encapsulated islet transplantation. The kidney capsule has the highest pO 2 measurements compared to other anatomical sites. The intramuscular space (rectus abdominis) and general intraperitoneal space have lower pO 2 levels compared to the pancreas, liver, subcutaneous and kidney capsule. The bursa omentalis site was not found to be significantly different to that of the pancreas or the general intraperitoneal space. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 (individual P values given in Supplementary Table 3 ). One-way ANOVA with Fisher's least significant difference for multiple comparisons, and three steady-state measurements were taken for each anatomical site from the same primate (n = 3 NHPs). Box and whisker with median, upper and lower quartile ranges, outliers, 1.5× IQR, and individual data points overlaid. Anatomical schematic in a adapted from ref. 67 , Baishideng Publishing Group. c, Histograms depicting the degree of PFO sphere coverage for each of the primate retrievals at 1 month (SLG20 and Z1-Y15) and 4 months (Z1-Y15) post-transplantation in NHPs. White and light colours depict little sphere coverage by fibrosis and dark red shading depict spheres mostly fibrosed. The SLG20 spheres with encapsulated islets were completely adhered to omental tissue and are depicted as mostly fibrosed dark red. Z1-Y15 encapsulated islets at 1 month: 121, 90, 152 and 125 spheres assessed from n = 4 NHPs; Z1-Y15 encapsulated islets at 4 months: 160, 167 and 128 spheres assessed from n = 3 NHPs. d, Left: estimated percentages of viable cells within islet cell clusters following live/dead staining performed pre-encapsulation (naked), post encapsulation in Z1-Y15 alginate (pretx) and post retrieval of non-fibrosed spheres at 1 month and 4 months. Naked: n = 144 total islets assessed, median viability 95.0%; post-encapsulation: n = 191 total islets, median viability 94.0%; Z1-Y15: 1-month retrieval: n = 133 total islets over 4 NHP retrievals, median viability 93.5%; Z1-Y15: 4-month retrieval: n = 69 total islets over 2 NHPs, median viability 90.0%; 25-50 islets were scored per primate; median value per group depicted. Viability scores were analysed using the Wilcoxon signed-rank test to assess whether median viability was significantly different from 75%. Seventy-five per cent was chosen as the biological reference because it is the cutoff for islet preparations suitable for clinical intraportal islet transplantation. Six out of seven encapsulated islet preparations demonstrated significantly higher viability than 75% from pre-encapsulation (naked) and post-encapsulation to post retrieval from NHP (P < 0.05; Wilcoxon signed-rank test; two-tailed; individual P values presented in Supplementary 
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NATuRe BIOMedICAl eNgINeeRINg retrieval in case of adverse side effects; and (5) facilitate the engraftment process whereby secreted insulin can be effectively delivered to target tissues for blood glucose homeostasis 47 . Previously investigated sites may be better or worse equipped for each of these parameters. For instance, the subcutaneous site may be the most easily accessible but is restricted by the space available to accommodate a large material or cell graft. The peritoneal cavity may provide a large space but is restricted by sedimentation and clumping in the lowest point of the site in bipedal animals, therefore hindering nutritional diffusion. We compared the pO 2 of alternative transplantation sites to begin probing the suitability of alternative sites and to identify sites that may require additional tissue engineering strategies in the future 48 . First, we determined the proper fraction of inspired oxygen to use during surgical intubation of NHPs to ensure that the pO 2 measurements of the various transplantation sites adequately recapitulated a NHP breathing normal air ( Supplementary Fig. 2 ). Subsequent steady-state measurements indicated that the average pO 2 levels within the general intraperitoneal space were indeed low compared to the pancreas (30.7 ± 1.6 mmHg compared with 39.6 ± 3.2 mmHg, respectively) ( Fig. 2c ; Supplementary Table 2 ). The bursa omentalis showed a trend of increased average pO 2 compared to the general intraperitoneal space, but this was not found to be significantly different (35.1 ± 3.2 mmHg compared with 30.7 ± 1.6 mmHg, respectively). The kidney capsule was found to yield the highest pO 2 measurements compared to other sites (48.7 ± 1.3 mmHg). This property may confer the positive function of naked islets post transplantation compared to other sites in rodents; however, the invasive surgical procedure and organ manipulation required seriously hampers human translation of this site 49 . Interestingly, the subcutaneous site yielded higher pO 2 levels than anticipated (39.0 ± 2.1 mmHg); however, this site in its natural state has not proved to be an effective transplantation site for naked or encapsulated islets 41, 46, 48 .
The bursa transplantation site demonstrated a trend of decreased average pO 2 levels compared to the pancreas (35.1 ± 3.2 mmHg compared with 39.6 ± 3.2 mmHg, respectively), although this was not found to be significant (individual P values presented in Supplementary Table 3 ). Normally, in situ islets contain a rich microvasculature and fenestration by endothelial cells, but this is mostly lost during the isolation and encapsulation process, leading to some degree of cell hypoxia, especially in the core of the cell clusters 50 . It has been previously reported that exposure of immunoisolated islets to hypoxic conditions in vitro can diminish islet function 51 . However, even when reducing the fraction of oxygen from 21% (normoxia) to 10% (hypoxia), encapsulated islets can remain viable and glucose responsive, albeit with a decrease in intracellular signalling of coupling factors important in the insulin secretion pathway 52 . As the oxygen level measurements in the bursa site reflected on average an 11% reduction in pO 2 levels compared to the pancreas, the oxygen levels in the bursa site may be sufficient to support encapsulated endocrine graft function for as long as the microsphere surface remains devoid of fibrotic overgrowth to ensure free nutritional exchange.
Z1-Y15 spheres containing allogeneic islets in NHPs
We sought to investigate the potential of the improved sphere formulation and the improved transplantation methods to support allogeneic islets without immune suppression in NHPs. Pancreatic islets were isolated from cynomolgus macaques, encapsulated within Z1-Y15 modified alginate spheres (1.5 mm in size), and transplanted into the bursa omentalis of non-diabetic cynomolgus monkeys ( Supplementary Table 4 ). Non-diabetic NHPs were chosen for this experiment to remove any potential for hyperglycaemia-induced glucotoxicity on islet viability and the differences in metabolic profiles between NHPs and humans [53] [54] [55] [56] . Diabetic NHPs require approximately four times as much exogenous insulin compared to humans in order to maintain blood glucose homeostasis (NHPs: 2-3 UI per kg per day; UIC islet transplant patients: 0.5-0.7 UI per kg per day) 57, 58 . NHP islets have also been shown to secrete higher amounts of insulin during in vitro glucose challenges compared to human islets, which may be related to the higher insulin requirements of the species 56 . These species-related metabolic differences may make any information concerning factors such as the optimal number of islets per sphere, curative dose of islets and spheres, or longevity of encapsulated islet graft function difficult to compare between NHP and humans. For these reasons and as a proof of concept, Z1-Y15 spheres containing allogeneic islets were retrieved 1 month and 4 months post transplantation into the bursa omentalis of non-diabetic NHPs to assess the biocompatibility of the spheres (PFO) and the presence of viable endocrine tissue.
One month and 4 months post transplantation, the Z1-Y15 spheres with encapsulated islets were translucent and well distributed within the bursa site ( Fig. 2b; Supplementary Fig. 3 ; Supplementary Video 2). Spheres with encapsulated islets easily dissociated from excised omental tissue and were free of PFO, as shown by inverted phase-contrast images ( Fig. 3a; Supplementary Fig. 4 ). This is in contrast to control empty SLG20 alginate spheres, which exhibited substantially more cellular overgrowth. Cells on the surface of the retrieved spheres were dissociated and analysed using flow cytometry for CD68 + /CD11b + macrophages, the predominant mediators of FBRs to implantable materials 21 . Z1-Y15 spheres with encapsulated islets showed decreased macrophage cellular attachment compared to SLG20 empty alginate spheres ( Fig. 3b; Supplementary Fig. 5 ). For comparison, SLG20 spheres with encapsulated allogeneic islets were also transplanted into the bursa omentalis site. No free spheres could be retrieved from the excised omental tissue as the spheres were surrounded in fibrotic tissue after 1 month ( Supplementary  Fig. 6 ). PFO was quantified, and Z1-Y15 spheres with encapsulated islets were substantially less fibrosed than the retrieved SLG20 spheres with encapsulated islets ( Fig. 3c ; Supplementary Table 5 ). PFO scores were further reduced when Z1-Y15 spheres were transplanted into the bursa omentalis site compared to the general intraperitoneal space, which may be indicative of a reduction in material fibrosis by limiting sphere clumping ( Supplementary Tables 1, 5 ). Interestingly, cynomolgus islets encapsulated in SLG20 spheres resulted in fibrosis 1 month post allogeneic transplantation in NHPs, but the same SLG20 formulated spheres with cynomolgus islets enabled long-term glycaemic control in immune-competent C57BL/6J mice as a xenogeneic transplant model ( Supplementary  Fig. 7a,b ). The encapsulated islets demonstrated marginal fibrosis when retrieved from the intraperitoneal space of the mice after 1 year ( Supplementary Fig. 7c ). This result further highlights the disconnect between NHPs and the most predictive mouse model (C57BL/6J) for testing islet cell encapsulation technologies.
The Z1-Y15 formulation was found to provide long-term protection of viable allogeneic tissue in NHPs ( Fig. 3d-g) . Viability assessments were performed on the encapsulated islets to estimate the number of live cells within the whole islet cell clusters. This method of viability assessment is employed in clinical islet transplantation, in which the gross islet lot viability must be over 75% in order to be deemed suitable for intraportal islet transplantation in the National Institutes of Health (NIH)-sponsored clinical trial by the Clinical Islet Transplantation consortium 58, 59 . Islet viability scores were determined pre-encapsulation (naked), post encapsulation (pretx) and post retrieval at 1 month and 4 months (Fig. 3d) . The viability scores of the islets at each of the time points were then analysed using the Wilcoxon signed-rank test to assess whether median viability was significantly different from 75%. Six out of the seven encapsulated islet preparations demonstrated significantly higher viability than 75% from pre-encapsulation and post-encapsulation to post retrieval from NHPs (Supplementary Table 6 ). Encapsulated islets from one primate (CN8800) were retrieved at 4 months and exhibited PFO and non-viable islets. At the time of transplantation, Articles NATuRe BIOMedICAl eNgINeeRINg this same lot of encapsulated islets was also transplanted into a separate primate (CN8801) that yielded viable islets without PFO when retrieved at 4 months. These distinct results for the same lot of material and islets led us to hypothesize that the cause of PFO formation in the one primate may be related to undocumented differences in the transplant procedure or to natural animal variability when using non-inbred NHP models.
The retrieved Z1-Y15 encapsulated islets also demonstrated conservation of functional endocrine tissue ( Fig. 3e-g) . The islets stained densely for dithizone at both 1 month and 4 months post transplantation (Fig. 3e ). Dithizone is a stain that binds zinc ions within mature insulin granules and is employed during islet isolation to discern endocrine tissue from non-beta cell tissue. The hallmark phenotype of beta cells is an ability to detect glucose changes in extracellular solutions and secrete insulin. This functional capacity of the retrieved encapsulated islets was tested using both static and dynamic glucose challenge assays.
First, glucose-stimulated insulin secretion of the encapsulated islets was measured, whereby islets were statically incubated in a low (2 mM) and high (18 mM) glucose solution for 1 h, and the amount of insulin secreted into the supernatant was quantified. The Z1-Y15 encapsulated allogeneic islets secreted significantly higher levels of insulin under high glucose compared with low glucose at both 1and 4-month retrieval time points (Fig. 3f ). The glycaemic induced stimulation index was lower at 4 months compared with 1 month; however, this may be related to a less than optimal preparation of islets and the smaller numbers of primates tested at 4 months.
Second, intracellular coupling factors that are important mediators in the insulin secretion pathway were measured using a dynamic microfluidic based perifusion glucose challenge assay 52, 60 . In beta cells, glucose-induced insulin secretion is a complex process involving glucose metabolism, mitochondrial energy production, closing of ATP-dependent potassium ion channels, opening of voltage-dependent calcium ion channels, calcium influx and insulin granule fusion with the cell membrane for insulin secretion, which has a biphasic and oscillatory kinetic pattern 61 . By loading islets with fluorescent dyes (Rh123 and Fura-2), beta cell activity was dynamically assessed to probe mitochondrial activity and membrane ion channel performance after stimulation with high glucose. Retrieved encapsulated islets demonstrated similar mitochondrial membrane potential changes (Δ Ψ m ) and intracellular calcium influx ([Ca 2+ ] i ) levels after stimulation with high glucose (18 mM) compared with encapsulated islets tested pre-transplantation ( Fig. 3g ). These responses of the retrieved encapsulated islets are indicative of proper mitochondrial energy production and functional voltagedependent calcium ion channels, which suggest that the intracellular machinery important for insulin secretion are conserved within the retrieved encapsulated islets.
In previous studies, it was suggested that the chemical modification of alginate spheres using a triazole ring containing small molecules confers a distinct surface that reduces macrophage activation 26 . This effect did not appear to be directly correlated to bulk sphere physical properties, such as the Young's modulus, permeability, surface roughness or protein adsorption, for the sphere formulations tested 26 . It was previously shown that the adherence of CD68 + /CD11b + macrophages correlates with a significant FBR and fibrosis of alginate spheres 21 . The adherence of this cell subtype to Z1-Y15 empty spheres was significantly reduced compared to control unmodified alginate formulations 26 , and we now show a similar reduction in this immune cell population even with the presence of allogeneic cells in NHPs (Fig. 3b ). Activated macrophages are known to recruit myofibroblasts (SMA-positive), which deposit extracellular matrix proteins (collagen I/III, laminin and fibrinogen) in conjunction with macrophages to form the nutrient-restrictive matrix 32,62-65 . We hypothesize that the Z1-Y15 chemical modification specifically modulates macrophage activation upstream, which in turn significantly reduces the recruitment of myofibroblasts, the major contributor to downstream fibrosis. The molecular interactions that lead to this macrophage modulation remain unclear but are actively being investigated in our laboratory.
Through the combination of an antifibrotic Z1-Y15 encapsulation material and an alternative transplantation technique into the bursa omentalis, long-term protection of viable and glucoseresponsive allogeneic islets was achieved in NHPs without any immunosuppression. This approach can similarly be used for a broad spectrum of applications, including localized drug delivery and allogeneic cell-based protein therapies, to better manage protein-deficiency diseases such as Parkinson disease, haemophilia or lysosomal storage disorders. Importantly, considering that clinical trials conducted with encapsulated cadaveric islets were shown to be safe and well tolerated, we believe that similar evaluation in patients using these materials and transplantation methods is warranted and may provide therapeutic benefit to a select group of patients with diabetes and with severe hypoglycaemic unawareness.
Methods
Laparoscopic implantation and retrieval of empty alginate spheres formulations from the general intraperitoneal space of NHPs. All transplant procedures involving both NHPs and mice were compliant with the relevant ethical regulations, including the guidelines of the NIH, and all procedures were approved in protocols by the animal care committee at the UIC. Each of the sphere formulations used in the human clinical trials (A-PLO-A, UPMVG-Ba 2+ and UPMVG-Ca 2+ /Ba 2+ ) were produced using previously reported methods [12] [13] [14] [15] . The spheres were either produced at each respective institution and shipped to the UIC or produced by the original inventor team under current good manufacturing practice conditions at the UIC for implantation into non-diabetic NHPs. The control alginate SLG20-Ba 2+ and the chemically modified alginate derivative spheres (Z1-Y19-Ba 2+ , Z2-Y12-Ba 2+ and Z1-Y15-Ba 2+ ) were produced at MIT using previously reported methods 26 and shipped for implantation into nondiabetic NHPs. The spheres were implanted laparoscopically and evenly distributed around lobes of the liver in the general intraperitoneal space of the abdominal cavity, as previously described 17 . The empty plain alginate spheres were retrieved laparoscopically using saline lavages to flush free spheres after 7 days and 1 month post implantation. The SLG20 alginate-Ba 2+ and chemically modified alginate derivative spheres were retrieved using the same laparoscopic procedure after 2 weeks, 1 month and 6 months post implantation. The retrieved spheres were then assessed for fibrosis and processed for histological analyses. Omental tissue biopsy specimens containing spheres were also processed for histological analyses.
Z1-Y15 small-molecule synthesis.
To synthesize the Z1-Y15 small molecule, 4-propargylthiomorpholine 1,1-dioxide (1 equiv.) was added to a round bottom flask and dissolved in a methanol:water (5:1) mixture. Then tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (0.25 equiv.), triethylamine (0.25 equiv.) and copper(I) iodide (0.1 equiv.) was added. The mixture was purged with nitrogen for 5 min and cooled to 0 °C. Then 11-azido-3,6,9-trioxaundecan-1-amine (6.30 g, 28.86 mmol, 1 equiv.) was added. The mixture was stirred at room temperature for 5 min and subsequently heated to 55 °C overnight. The reaction mixture was left to cool to room temperature and filtered using a Buchner funnel through 413 filter paper to filter off any insoluble material. The filtrate was washed three times with 50 ml methanol and the solvent was removed under reduced pressure. The crude material was purified via liquid chromatography and characterized using NMR and high-resolution mass spectroscopy. NHP pancreatectomy. The donor pancreas procurement was performed under general anaesthesia. Using a midline incision, both splenorenal and splenocolic ligaments were divided to mobilize the spleen and pancreatic tail. The head of the pancreas and second portion of the duodenum were mobilized using a Kocher manoeuvre. The lesser sac was opened and dissected exposing the superior mesenteric artery and supraceliac aorta and infra renal aorta. After administration of heparin (200 units per kg), the aorta was cannulated just above its bifurcation using a 14 G, 1.88 inch catheter (BD Angiocath). Both the supraceliac aorta and the inferior mesenteric artery were ligated and the animal was exsanguinated. Cold saline slush was immediately placed into the lesser sac surrounding the body of the pancreas. The pancreas was flushed with cold UW solution (600-800 ml). The body and neck of the pancreas were carefully excised. The duodenum was carefully separated off the pancreatic head to identify and cannulate the pancreatic duct using a 24 G, 0.75 inch winged cannula (BD Insyte Autoguard Winged).
NHP islet isolation.
Cynomolgus monkey islets were isolated from donors using a previously reported method 57 . Briefly, the pancreas was perfused with enzyme solution (10-15 ml, collagenase type V; 3.3 mg ml -1 in cold Hank's balanced salt solution (HBSS), Sigma-Aldrich) and cut into 8-10 small pieces. The pancreatic tissue was digested in a 125-ml glass Erlenmeyer flask in a 37 °C water bath under gentle agitation for 12-15 min. At 10 min, the first tissue sample was taken from the flask using a sterile transfer pipette to assess the size of the dissociated tissue and the percentage of free islets. Samples were assessed with dithizone staining under bright-field microscopy until the pancreatic tissue was evenly broken down, and 80% or more of the islets were free without obvious fragmentation. At this point, the digestion process was quenched by diluting the enzyme-tissue solution with 500 ml of cold HBSS containing 10% fetal bovine serum (FBS). The tissue was washed three times with the cold HBSS solution by centrifugation (200 g for 1 min). The digested tissue was then purified using a discontinuous ficoll density gradient (density: 1.108 g ml -1 , 1.196 g ml -1 and 1.069 g ml -1 ) (Mediatech). Based on the volume, the tissue was divided into 50-ml conical tubes (0.5 ml tissue concentration for each tube). The centrifuge speed for purification was 640 g for 15 min. The islet interface between the density of 1.196 and 1.069 was aspirated manually and washed three times with CMRL supplemented culture medium containing 10% FBS, 0.2% ciprofloxacin, and 0.1% insulin transferrin-selenium. The purified islets were then cultured overnight at 37 °C and 5% CO 2 .
NHP islet encapsulation within Z1-Y15 alginate. The encapsulation of cynomolgus monkey islets within Z1-Y15 alginate was performed at the UIC in conjunction with researchers from the MIT according to previously reported methods 26 . Before encapsulation, all buffers were sterilized by autoclave, and alginate solutions were sterile-filtered through a 0.2-μ m filter. All experimental procedures were conducted in a biosafety cabinet. Cynomolgus monkey islets were collected and washed twice with calcium-free Krebs-Henseleit solution (4.7 mM KCl, 25 mM HEPES, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 ·7H 2 O, 135 mM NaCl, pH ~7.4, ~290 mOsm) by centrifugation at 200 g for 1 min at room temperature. After the final wash, the entire supernatant was carefully removed, leaving an islet pellet with little residual liquid. Sterile cotton swabs were then used to remove any residual washing solution on the sides of the conical tube, which would dilute the alginate solution.
The Z1-Y15 conjugated UP-VLVG alginate was initially dissolved at 5% wt/ vol. in 0.8% saline overnight. This was then blended overnight with a 3% wt/vol. SLG100 (also dissolved in 0.8% saline) at a volume ratio of 70% Z1-Y15-VLVG alginate to 30% SLG100. Five millilitres of the final Z1-Y15 working alginate solution was added to the islet pellet at an islet seeding density of 1,000 islets per 1 ml Z1-Y15 alginate solution. The mixture was gently agitated to uniformly disperse the islets within the Z1-Y15 alginate solution and transferred to a 5 ml syringe with an 18 G blunt-tipped needle (SAI Infusion Technologies). An electrostatic droplet generator was set up in the biosafety cabinet as follows: an ES series 0-100-kV, 20-watt high-voltage power generator (Gamma ES series, Gamma High-Voltage Research) was connected to the blunt-tipped needle. A glass dish containing a 20 mM barium and 5% mannitol solution (Sigma-Aldrich) was then grounded via metal forceps. A syringe pump (Pump 11 PicoPlus, Harvard Apparatus) was oriented vertically and used to extrude alginate droplets into the gelation solution over a period of 20 min and gelled for an additional 5 min. The settings of the PicoPlus syringe pump were 12.06 mm diameter and 0.18 ml min -1 flow rate. After the spheres were formed, they were collected and washed with HEPES buffer (15.428 g of NaCl, 0.70 g of KCl, 0.488 g of MgCl 2 ·6H 2 O, 50 ml of HEPES (1 M) buffer solution (Gibco, Life Technologies) in 2 litres of deionized water) four times. The spheres were then washed two times in 0.8% saline and two more times with culture media, CMRL1066 Supplemented (Mediatech) containing 0.2% ciprofloxacin, 10% FBS and 0.1% insulin transferrin-selenium (100× ) (Gibco, Life Technologies). The Z1-Y15 spheres with encapsulated islets were then cultured for 2 days overnight before transplantation in NHPs.
Bursa omentalis laparoscopic transplantation of encapsulated islets. Under general anaesthesia, a small supra umbilical midline incision was performed to place a 8 mm trocar (ENDOPATH XCEL, Ethicon Endo-Surgery). The camera was introduced to confirm the trocar location. Pneumoperitoneum was created with CO 2 at a pressure of 10-14 mmHg, and two additional small incisions were performed on the left and right flank. Then, 5 mm trocars were inserted into the peritoneal cavity. An endoscopic grasping forceps (Endo Dissect, Covidien) and endoscopic scissors (Endo Shears, Covidien) were inserted into each of the two trocars. The stomach was gently lifted using the laparoscopic grasper and a small incision was made into an avascular portion of the gastrocolic ligament (anterior layer of the greater omentum below the greater curvature of the stomach and above the transverse colon). A 2-ml pipette was connected by silicone tubing to a 60-ml lavage syringe containing the spheres. The pipette was then placed into the lesser sac and the spheres were gently infused. Once the spheres had been infused into the bursa omentalis, the stomach was gently lowered to seal the opening. The trocars were removed and the three small incisions were closed in two layers using 3-0 Vicryl (Ethicon) for the muscle and 5-0 Vicryl (Ethicon) for the skin (subcuticular). Bupivicaine was infused along the incision line to reduce postoperative pain.
Retrieval of encapsulated cynomolgus monkey islets.
Under general anaesthesia and using the previously described laparoscopic technique, 20-30 ml of normal saline was used as a lavage to flush free spheres from the intraperitoneal space. Free spheres in the lavage solution in the general intraperitoneal space were then aspirated and collected for analyses. For spheres transplanted into the bursa omentalis, the greater omentum was pulled through the laparoscopic camera port incision to exam the sphere laminar distributions. The greater omentum containing spheres was then resected and agitated with saline in a surgical bowl to dissociate spheres from the greater omentum. In the case when no free spheres were found in the lavage solutions or from the agitated greater omentum resections, biopsies of omental tissue containing spheres were removed for histological analyses.
Inverted phase-contrast imaging. For phase-contrast imaging, retrieved materials were gently washed twice with Krebs buffer and transferred into 35-mm Petri dishes for phase-contrast microscopy using an Evos Xl microscope (Advanced Microscopy Group). Images were then converted to black and white, and colours inverted using ImageJ software. The colours were inverted in order to see the sphere outline as well as the presence of islets within the spheres. Original images are shown in the top right corner of each inverted phase-contrast image. For bright-field imaging of retrieved materials, samples were gently washed using Krebs buffer and transferred into 35-mm Petri dishes for bright-field imaging using a Leica stereoscopic microscope.
Fibrosis scoring of retrieved spheres. The retrieved spheres were assessed using a bright-field microscope for the degree of fibrotic overgrowth as per a previously reported method 66 . The degree of fibrotic overgrowth was determined by categorizing the retrieved spheres for the percentage of the sphere surface area that was covered by overgrowth: 0 < 25%, 25-50%, 50-75%, 75-100%. Data are presented as the percentage of spheres assessed in each category for each primate. The total number of spheres assessed per primate retrieval is provided in the Supplementary Information.
Flow cytometry analysis of cells dissociated from retrieved spheres.
Single-cell suspensions of cells from the surfaces of freshly retrieved spheres were prepared using a gentleMACS Dissociator (Miltenyi Biotec) according to the manufacturer's protocol. Single-cell suspensions were prepared in PEB dissociation buffer (1× PBS, pH 7.2, 0.5% BSA and 2 mM EDTA) and suspensions were passed through 70-μ m filters (catalogue no. 22363548, Fisher Scientific). Single-cell populations were then subjected to red blood cell lysis with 5 ml of 1× RBC lysis buffer (catalogue no. 00-4333, eBioscience) for 5 min at 4 °C. The reaction was terminated by the addition of 20 ml of sterile 1× PBS. The remaining cells were centrifuged at 300-400 g at 4 °C and resuspended in a minimal volume (~50 μ l) of eBioscience Staining Buffer (catalogue no. 00-4222) for antibody incubation. All samples were then co-stained in the dark for 25 min at 4 °C with two of the fluorescently tagged monoclonal antibodies specific for the cell markers CD68 (1 μ l (0.5 μ g) per sample; CD68-Alexa647, Clone KPI, catalogue no. sc-20060, Santa Cruz Biotechnology) and CD11b (1 μ l (0.2 μ g) per sample; CD11b-Alexa-488, Clone M1/70, catalogue no. 101217, BioLegend). A volume of eBioscience Flow Cytometry Staining Buffer (2 ml; catalogue no. 00-4222, eBioscience) was then added, and the samples were centrifuged at 400-500 g for 5 min at 4 °C. Supernatants were removed by aspiration, and this wash step was repeated two more times with staining buffer. Following the third wash, each sample was resuspended in 500 μ l of Flow Cytometry Staining Buffer and passed through a 40-μ m filter (catalogue no. 22363547, Fisher Scientific) for eventual analysis using a BD FACSCalibur (catalogue no. 342975), BD Biosciences). For proper background and laser intensity settings, unstained, single antibody and IgG (labelled with either Alexa-488 (catalogue no. 400625, BioLegend) or Alexa-647 (catalogue no. 400526, BioLegend)) controls were also run.
Histology of retrieved freely floating spheres. Post retrieval, freely floating spheres were rinsed three times with PBS and fixed in 10% formalin overnight.
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After fixation, the spheres were rinsed twice with PBS, and dehydrated in gradually ascending ethanol solutions for 20 min each time. The spheres were cleared in xylene for 10 min, and incubated in a 50/50 solution of xylene and paraffin overnight at 57 °C. On day 3, the spheres were transferred to paraffin twice for 1 h each, and then embedded in a paraffin mould. Subsequently, embedded spheres were sectioned at 5-μ m thickness onto positively charged lysine microscope slides. Tissue sections were then stained for H&E to assess pericapsular cellular overgrowth.
Histology of omental biopsy specimens containing spheres. Biopsy specimens containing embedded spheres were fixed in 10% formalin overnight, rinsed twice with PBS and stored overnight in 70% ethanol. Biopsies were further dehydrated the next day in ascending ethanol solutions, cleared in xylene and embedded in a paraffin block. Subsequently, embedded biopsies were sectioned at 5-μ m thickness and stained for H&E to assess tissue overgrowth of the spheres. If morphological observation of H&E stained tissue sections showed multilayer cellular overgrowth of the spheres, immunohistochemistry was performed on the adjacent tissue sections to investigate the cellular populations involved in the PFO. Sections were immunofluorescently labelled for CD11b + myeloid cells and alpha-SMA-positive myofibroblasts. Slide sections were deparaffinized, and rehydrated tissue sections were immersed in citrate buffer (pH 6) to perform the heat-induced epitope retrieval. Tissue sections were then rinsed with Tris-buffered saline plus 0.025% Triton X-100 and blocked with goat normal serum for 1 h at room temperature. Primary antibodies, mouse IgG1 against CD11b (1:100 clone ICRF44; catalogue no. ab34216, Abcam) and α -SMA (1:100 clone IA4; catalogue no. ab7817; Abcam), were applied on serial sections and incubated overnight at 4 °C. After rinsing with Tris-buffered saline plus 0.025% Triton X-100, fluorescently labelled secondary antibodies, Alexa Fluor 594 anti-mouse (1:200; catalogue no. A-11032; Invitrogen), were applied and incubated for 1 h at room temperature. Nuclear counterstain (4,6-diamidino-2-phenylindole (DAPI)) was then applied and the coverslips mounted. All stained tissue sections were viewed using a Leica DM 200 microscope and images were captured using a QICAM Fast1394 digital camera and processed with the Qcapture Pro5.1 program. pO 2 measurements of various transplantation sites in NHPs. Monkeys were sedated and anaesthetized in accordance with approved animal protocols at the University of Illinois at Chicago. The animals were ventilated with room air to maintain physiological arterial pO 2 . This was determined by measuring the pO 2 (mm Hg -1 ), total haemoglobin (g dl -1 ) and O 2 saturation (%) of the NHPs before intubation (while sedated but breathing normal air) and post intubation with different fractions of inspired oxygen. A left femoral arterial line was inserted to facilitate repeated blood draws (1 ml) from the cynomolgus monkey. Following the pre-intubation blood draw, the animal was intubated and placed on different fractions of inspired oxygen (50-21%) for 3 min. Blood samples were collected from the arterial line and placed in a Blood Gas Analyzer cassette. Arterial pO 2 , total haemoglobin and O 2 saturation were analysed using a IDEXX VetStat Electrolyte and Blood Gas Analyzer.
For pO2 measurements of transplantation sites in NHPs, no CO 2 pneumoperitoneum was used. A miniaturized Clark type oxygen probe (Unisense) was used to determine pO 2 inside the abdominal cavity. The working principle of the oxygen sensor is based on diffusion of oxygen through a silicone membrane to an oxygen-reducing cathode. The reducing cathode is polarized against an internal Ag/AgCI anode. This microscale sensor (2-3 μ m) can produce a minute current that is directly proportional to the oxygen tension in the tissue to which it is applied at high spatial resolution and at a fast response time (less than 0.3 s). In the animals tested, three pO 2 measurements were taken from each site. For intraperitoneal space, intramuscular and subcutaneous measurements, an 18 G needle was inserted into the site followed by insertion of the probe. For organ sites, the probe was placed in close proximity to the kidney, liver or pancreas. At each site, the probe was placed for 3-5 min before taking measurements. Dithizone staining. Dithizone was prepared by mixing dithizone (100 mg) in dimethylsulfoxide (10 ml) and HBSS (40 ml) (Sigma) and filtering through a 0.22µ m filter. Encapsulated monkey islets were placed in a 50-ml tube and 5 ml of dithizone was added and incubated for 3 min. The encapsulated islets were then quickly washed three times with 10 ml HBSS, followed by two 5-min incubations in fresh 10 ml HBSS to reduce background. The encapsulated islets were then placed in a 100-mm Petri dish and imaged using a bright-field microscope.
Islet viability. Cell viability of cynomolgus monkey islets was assessed post isolation, post encapsulation and post retrieval by dual fluorescence staining with the inclusion/exclusion dyes fluorescein diacetate (FDA) (Sigma) for live cells and propidium iodide (PI) (Sigma) for dead cells. Briefly, naked or encapsulated islets were rinsed twice with 10 ml HBSS (Mediatech) and then mixed with 2 ml of 0.46 µ M FDA and 14.34 µ M PI in HBSS. A fluorescence microscope with filters for FDA (excitation wavelength 488 nm, emission wavelength 520 nm) and PI (excitation wavelength 534 nm, emission wavelength 617 nm) was used to assess the viability of the islets. Percentages of total viable cells within 25-50 whole islets were estimated by a single operator trained in islet isolation protocols approved by the NIH-funded clinical trial by the Clinical Islet Transplantation consortium 58, 59 .
Glucose-stimulated insulin secretion. Glucose-stimulated insulin secretion was performed on encapsulated cynomolgus monkey islets post retrieval from NHPs. Encapsulated islets were collected in a 50-ml conical tube and quickly washed three times with saline (25 ml). Krebs-Ringer buffer (25 ml) containing 2 mM glucose (KR2) was then added to the encapsulated islets and the samples were incubated for 10 min. This wash step was repeated three times. Encapsulated islets were then placed into a Petri dish containing 20 ml of fresh KR2. Ten encapsulated islets were then handpicked under bright-field microscopy and placed into 12-µ m porous polyethylene terephthalate membrane sieves (Merck Millipore). Sieves containing islets were then transferred into 1 ml of KR2 solution for 30 min (pre-wash). The sieves were then transferred into fresh 1 ml of KR2 solution for 1 h (wash). The sieves were transferred to 1 ml of fresh KR2 solution for 1 h (Low). The sieves were then transferred into 1 ml of Krebs-Ringer buffer containing 18 mM glucose (KR18; High) for 1 h. Supernatants were then collected from the low (KR2) and high (KR18) wells, and the insulin concentrations were quantified by human insulin ELISA (ALPCO) in duplicate without sample dilution.
Real-time fluorescence imaging of islet [Ca 2+
] i and ΔΨ m in response to dynamic glucose challenge. Real-time fluorescence imaging of islet [Ca 2+ ] i was performed in a microfluidic device modified for encapsulated islets 60 . In brief, encapsulated cynomolgus monkey islets were incubated with 5 μ M Fura-2/AM (Thermo Fisher Scientific) at 37 °C in KR2 buffer and 0.5% BSA for 35 min. The microfluidic device was then primed and placed on an inverted epifluorescence microscope (Leica DMI 4000B). Excess dye was washed out with KR2 buffer for 35 min at a rate of 500 μ l min -1 . Dual-wavelength Fura-2/AM dyes were excited ratiometrically at 340 and 380 nm. The changes in the [Ca 2+ ] i levels are expressed as F340/F380 (percentage increase from basal 2 mM glucose). Excitation wavelengths were controlled by excitation filters (Chroma Technology) mounted in a Lambda DG-4 wavelength switcher. Emission of Fura-2/AM was filtered using a Fura2/FITC polychroic beam splitter and a double-band emission filter (510 nm, 530 nm) (Chroma Technology; part no. 73.100bs). HCImage software (Hamamatsu) was used for imaging acquisition and analyses. Images were collected with a high-speed, high-resolution charge coupled camera (ORCA-R2 with ER chip 1344 × 1024, Hamamatsu).
Individual islet intracellular calcium responses were assessed with the following perifusion protocol: KR2 buffer (5 min), 18 mM glucose (20 min). The area under the curve for the time period of stimulation was calculated for each individual islet in order to statistically compare groups using one-way analysis of variance (ANOVA; P < 0.05 as significant).
Statistical analysis.
Data are expressed as box and whisker plots with median, upper and lower quartile ranges, outliers, and 1.5× interquartile range (IQR), unless specified otherwise. For NHPs transplanted with Z1-Y15 encapsulated allogeneic islets, n = 7; other primate numbers per treatment group are specified. Flow cytometry data were analysed for statistical significance by one-way ANOVA with Bonferroni multiple comparison correction. pO 2 values of various transplantation sites were analysed for statistical significance by one-way ANOVA and multiple comparisons using Fisher's least significant difference. Viability scores are presented as individual islets assessed at each time point from NHP experiments with non-fibrosed spheres. Median viability is depicted due to nonnormality. Median viabilities were analysed using the Wilcoxon signed-rank test to assess whether median viability was significantly different from 75% as a biological reference value. Glucose-stimulated insulin secretion data were analysed for statistical significance using the two-tailed Wilcoxon matched-pairs signed-rank test, and insulin concentrations from high and low-glucose supernatants from the same individual islet samples of Z1-Y15 spheres with encapsulated allogeneic islets. Low-and high-glucose insulin concentrations from Z1-Y15 spheres with encapsulated islets retrieved 1 month and 4 months after transplantation were compared using the non-parametric unpaired Mann-Whitney test. The [Ca 2+ ] i and Δ Ψ m changes in response to perifusion glucose challenge were analysed for statistical significance by one-way ANOVA by comparing the average area under the curve of [Ca 2+ ] i percentage of intracellular calcium influx and the average per cent decrease in Δ Ψ m (percentage change) of individual islets in response to 18 mM glucose stimulus. Statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software); *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article. Data availability. The datasets generated and/or analysed during this study are available from the corresponding author on reasonable request. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined. Sample size was chosen on the basis of previous experience with NHP cohort sizes, and by choosing a minimum number of NHPs per experimental group, owing to ethical concerns in sacrificing an excessive number of NHPs. We determined that reproducible results can be achieved by using 2 or 3 NHPs for material biocompatibility studies. For experiments with allogeneic islets, we increased the number to 3 or 4 NHPs per time-point group due to the presence of allogeneic tissue and to the higher potential for an immune response.
Data exclusions
Describe any data exclusions. No animals were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
Experimental findings were reliably reproduced. Six out of seven encapsulated-islet preparations demonstrated significantly higher viability than 75%, from preencapsulation (naked) to post-encapsulation (pretx) to post retrieval from NHPs. Encapsulated islets from one primate (CN8800) were retrieved at 4 months and presented with fibrosis and non-viable islets. At the time of transplantation, this same lot of encapsulated islets was also transplanted into a separate primate (CN8801) that yielded viable islets without fibrosis when retrieved at 4 months. These distinct results using the same lot of material/islets lead us to hypothesize that the cause of fibrosis in the one primate may be related to undocumented differences in the transplant procedure or to natural animal variability when using non-inbred NHP models.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
NHPs were randomly assigned to groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Surgeons were blinded during the implantation/transplantation and retrievals of empty spheres and of spheres containing allogeneic islets. This was to ensure that the same procedure/samples were collected for analysis. Viability assessments were performed by the same operator to reduce inter-operator error.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Prism vs 6 was used to make figures and to analyse numerical data for statistical significance. ImageJ was used to process inverted-phase contrast images by converting colors to black and white, and then by inverting in order to better visualize the presence of islets within retrieved spheres without fibrosis. All stained tissue sections were processed using the Qcapture Pro5.1 program to set appropriate gains and exposure times. HCImage software was used for image acquisition and analysis, for the microfluidic-based dynamic-glucose-challenge assay to monitor intracellular coupling factors/fluorescent intensity changes in islets post stimulation with high glucose.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used to generate the chemically modified alginate derivatives for the study.
